Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-13

Reporting Person: AJU IB Investment Co., Ltd. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-13	Common Stock	C	2292062	—	Acquired	2292062	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-13	Series C Preferred Stock	$	C	4000000	Disposed		Common Stock (1875293)	Indirect
2017-11-13	Series D Preferred Stock	$	C	888969	Disposed		Common Stock (416769)	Indirect

Footnotes

F1: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund.